X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES GSK PHARMA VENUS REMEDIES/
GSK PHARMA
 
P/E (TTM) x -3.4 60.2 - View Chart
P/BV x 0.1 11.2 1.1% View Chart
Dividend Yield % 0.0 2.6 -  

Financials

 VENUS REMEDIES   GSK PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
GSK PHARMA
Mar-18
VENUS REMEDIES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1262,760 4.6%   
Low Rs612,040 3.0%   
Sales per share (Unadj.) Rs301.8339.0 89.0%  
Earnings per share (Unadj.) Rs-24.941.4 -60.0%  
Cash flow per share (Unadj.) Rs2.545.9 5.5%  
Dividends per share (Unadj.) Rs035.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs293.3242.9 120.7%  
Shares outstanding (eoy) m12.3484.70 14.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.37.1 4.4%   
Avg P/E ratio x-3.857.9 -6.5%  
P/CF ratio (eoy) x36.752.3 70.3%  
Price / Book Value ratio x0.39.9 3.2%  
Dividend payout %084.5 0.0%   
Avg Mkt Cap Rs m1,154203,280 0.6%   
No. of employees `0000.9NA-   
Total wages/salary Rs m3935,234 7.5%   
Avg. sales/employee Rs Th4,026.1NM-  
Avg. wages/employee Rs Th425.0NM-  
Avg. net profit/employee Rs Th-331.8NM-  
INCOME DATA
Net Sales Rs m3,72428,715 13.0%  
Other income Rs m23545 4.1%   
Total revenues Rs m3,74729,260 12.8%   
Gross profit Rs m3955,059 7.8%  
Depreciation Rs m338380 89.0%   
Interest Rs m3542 17,715.0%   
Profit before tax Rs m-2755,222 -5.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m321,892 1.7%   
Profit after tax Rs m-3073,508 -8.7%  
Gross profit margin %10.617.6 60.2%  
Effective tax rate %-11.536.2 -31.7%   
Net profit margin %-8.212.2 -67.5%  
BALANCE SHEET DATA
Current assets Rs m2,63821,815 12.1%   
Current liabilities Rs m2,30515,999 14.4%   
Net working cap to sales %8.920.3 44.2%  
Current ratio x1.11.4 83.9%  
Inventory Days Days13564 213.0%  
Debtors Days Days4619 247.9%  
Net fixed assets Rs m4,87112,475 39.0%   
Share capital Rs m123847 14.6%   
"Free" reserves Rs m3,49619,726 17.7%   
Net worth Rs m3,61920,573 17.6%   
Long term debt Rs m1,3746 22,906.7%   
Total assets Rs m7,50939,475 19.0%  
Interest coverage x0.22,612.0 0.0%   
Debt to equity ratio x0.40 130,216.2%  
Sales to assets ratio x0.50.7 68.2%   
Return on assets %0.68.9 7.1%  
Return on equity %-8.517.1 -49.7%  
Return on capital %1.626.2 6.0%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m0564 0.0%   
Fx outflow Rs m5177,429 7.0%   
Net fx Rs m-517-6,865 7.5%   
CASH FLOW
From Operations Rs m5144,728 10.9%  
From Investments Rs m-123-1,042 11.8%  
From Financial Activity Rs m-387-3,066 12.6%  
Net Cashflow Rs m4620 0.7%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.2 10.2 1.8%  
FIIs % 0.6 23.8 2.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 15.4 431.2%  
Shareholders   20,121 102,036 19.7%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Higher; Energy & PSU Stocks Outperform(12:30 pm)

Stock markets in India are trading range-bound in the afternoon session. Among the sectoral indices, IT stocks and healthcare stocks are witnessing maximum selling pressure.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 14, 2018 12:55 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - WOCKHARDT LTD. COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS